Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A story on PatientEngagementHIT referenced a study published in the September 2021 issue of The American Journal of Managed Care® (AJMC®). The study, “Using CAHPS Patient Experience Data for Patient-Centered Medical Home Transformation,” found that Consumer Assessment of Healthcare Providers and Systems (CAHPS) surveys were considered actionable for primary care practices to use in patient-centered medical home transformation and in standardizing and coordinating care.
An article on RevCycleIntelligence highlighted a study in the July 2021 issue of AJMC®. The study, “Large Self-insured Employers Lack Power to Effectively Negotiate Hospital Prices,” found that market power is low in most metropolitan statistical areas for self-insured employers to negotiate hospital prices.
A story published on Spectrum News NY1 referred to an article published last year on AJMC.com, the website of AJMC®. The article, “Cancer Care Delays in COVID-19 Could Lead to Higher Morbidity, Mortality,” noted the fears experts have about the effect of delayed cancer screenings and treatments as a result of the pandemic.
An article published on BioWorld referenced "Biosimilars Roundup: Policy and Business Developments Signify a Busy August," a monthly column published on The Center for Biosimilars®, which discussed a controversy over payer policies for bevacizumab biosimilars.
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen